ARPA-H gene editing program THRIVE awards $160 million to seven research teams tasked with building scalable base-editing ...
A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered ...
Novartis already received FDA approval of ITVISMA as a gene therapy for the treatment of patients with SMA. Read why NVS ...
A new study describes a gene therapy strategy that uses the brain's own glymphatic transport system to distribute engineered viral vectors throughout the brain.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results